SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by BioSig Technologies, Inc. on May 15, 2015, covering events occurring on May 11, 2015. The filing details the entry into material definitive agreements regarding the exercise of investment options by two accredited investors.
Key Financial Metrics
The filing reports a specific capital raise event rather than periodic financial performance metrics. Key transaction figures include:
- Total Consideration Raised: $450,000
- Securities Issued: 450 shares of Series C Preferred Stock and Warrants to purchase 374,641 shares of Common Stock.
- Warrant Exercise Price: $1.50 per share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions for the reporting period.
Material Changes
The primary material change is the execution of Securities Purchase Agreements with two investors (Alpha Capital Anstalt and Brio Capital Master Fund Ltd.). This transaction resulted from the exercise of an option granted under Amendment Agreement No. 2 to a Securities Purchase Agreement dated April 12, 2013. The securities were sold in reliance on exemptions under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Outlook, Risks, and Unusual Items
Warrant Terms: The issued warrants include customary anti-dilution protections. They are exercisable immediately for cash. However, if no effective registration statement or current prospectus is available for resale after six months from issuance, the warrants may be exercised via a cashless exercise mechanism.
Risks and Contingencies: The filing notes that the summaries of the agreements are not complete and are qualified by reference to the full text of the exhibits. No specific forward-looking guidance or management commentary regarding future operations is provided in this document.
Investor Verification Checklist
- Verify the full terms of the Securities Purchase Agreements (Exhibits 10.1 and 10.2) to understand specific covenants and rights attached to the Series C Preferred Stock.
- Review the Form of Warrant (Exhibit 10.3) to confirm the precise mechanics of the anti-dilution provisions and cashless exercise conditions.
- Confirm the current status of any registration statements for the resale of the underlying common stock to determine if the six-month cashless exercise window is active.
- Check subsequent filings for the impact of this $450,000 capital infusion on the company's overall liquidity and working capital.